Harvard Price To Sales Ratio from 2010 to 2024

HBIO Stock  USD 2.20  0.01  0.46%   
Harvard Bioscience Price To Sales Ratio yearly trend continues to be very stable with very little volatility. Price To Sales Ratio is likely to drop to 1.72. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Harvard Bioscience's market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
2.02179955
Current Value
1.72
Quarterly Volatility
0.77138779
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Harvard Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harvard Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 3.8 M or Total Revenue of 96.8 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0022 or PTB Ratio of 4.65. Harvard financial statements analysis is a perfect complement when working with Harvard Bioscience Valuation or Volatility modules.
  
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

Latest Harvard Bioscience's Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Harvard Bioscience over the last few years. Price to Sales Ratio is figured by comparing Harvard Bioscience stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Harvard Bioscience sales, a figure that is much harder to manipulate than other Harvard Bioscience multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Harvard Bioscience's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harvard Bioscience's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.98 X10 Years Trend
Very volatile
   Price To Sales Ratio   
       Timeline  

Harvard Price To Sales Ratio Regression Statistics

Arithmetic Mean1.48
Geometric Mean1.34
Coefficient Of Variation52.03
Mean Deviation0.56
Median1.09
Standard Deviation0.77
Sample Variance0.60
Range2.9208
R-Value(0.04)
Mean Square Error0.64
R-Squared0
Significance0.89
Slope(0.01)
Total Sum of Squares8.33

Harvard Price To Sales Ratio History

2024 1.72
2023 2.02
2022 1.01
2021 2.39
2020 1.62
2019 0.99
2018 0.94

About Harvard Bioscience Financial Statements

Harvard Bioscience investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Harvard Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Sales Ratio 2.02  1.72 
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
(0.33)
Revenue Per Share
2.258
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.02)
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.